- Home
- FTDR vs WGS Comparison
FTDR vs WGS Comparison
Compare FTDR & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FTDR | WGS |
|---|---|---|
| Founded | 1971 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Retail: Computer Software & Peripheral Equipment |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.6B |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | FTDR | WGS |
|---|---|---|
| Price | $56.42 | $83.24 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $59.75 | ★ $138.13 |
| AVG Volume (30 Days) | 433.5K | ★ 650.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.98 | N/A |
| EPS | ★ 3.38 | N/A |
| Revenue | ★ $1,843,000,000.00 | N/A |
| Revenue This Year | $15.25 | $41.16 |
| Revenue Next Year | $5.74 | $25.90 |
| P/E Ratio | ★ $16.62 | $1,251.58 |
| Revenue Growth | ★ 3.54 | N/A |
| 52 Week Low | $35.65 | $55.17 |
| 52 Week High | $70.14 | $170.87 |
Technical Indicators
Market Signals| Indicator | FTDR | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 39.74 | 37.38 |
| Support Level | $55.56 | $86.12 |
| Resistance Level | $58.38 | $93.23 |
| Average True Range (ATR) | 1.67 | 5.68 |
| MACD | -0.23 | 1.53 |
| Stochastic Oscillator | 9.38 | 43.11 |
Price Performance
Historical ComparisonAbout FTDR Frontdoor Inc.
Frontdoor Inc is a United States-based company that provides home service plans. It owns multiple home service brands including American Home Shield, HSA, OneGuard, and Landmark brands. Through its home service plans, the company helps its customers maintain their homes and protect against costly and unexpected breakdowns of essential home systems and appliances.
About WGS GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.